A phase I randomized, controlled, dosage-escalation trial to evaluate the immunogenicity, safety, and reactogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in healthy adults 18 to 45 years of age.

Trial Profile

A phase I randomized, controlled, dosage-escalation trial to evaluate the immunogenicity, safety, and reactogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in healthy adults 18 to 45 years of age.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2014

At a glance

  • Drugs Malaria vaccine (Primary)
  • Indications Malaria
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 03 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 21 Nov 2012 New source identified and integrated (Vanderbilt University Institutional Review Board; 060977).
    • 02 Feb 2010 Planned end date changed from 1 Nov 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top